<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age/><report-id>PHHY2012IT079620</report-id><gender>female</gender><reactions><reaction>Loss of consciousness</reaction><reaction>Clinical lack of efficacy</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>GILENYA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CIPRALEX</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>TOPAMAX</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LYRICA</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Multiple sclerosis</indication></indications><outcomes/><country>Italy</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149680_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152625</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>5</safetyreportversion>
		<safetyreportid>PHHY2012IT079620</safetyreportid>
		<primarysourcecountry>IT</primarysourcecountry>
		<occurcountry>IT</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-09-11</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-21</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012IT079620</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>175292</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>175288</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>IT</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>IT</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>IT</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientagegroup>5</patientagegroup>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>Loss of consciousness</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Loss of consciousness</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Loss of consciousness</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120323</reactionstartdate>
				<reactionfirsttime>61</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Clinical lack of efficacy</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Lack of drug effect</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug ineffective</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>GILENYA</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugbatchnumb>S0023</drugbatchnumb>
				<drugauthorizationnumb>22-527</drugauthorizationnumb>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>0.5 mg, daily</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-01-23</drugstartdate>
				<drugstartperiod>61</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-20</drugenddate>
				<drugtreatmentduration>303</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>FINGOLIMOD</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Loss of consciousness</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Loss of consciousness</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CIPRALEX</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>10 mg, UNK</drugdosagetext>
				<drugdosageform normalized="coated tablet">Coated tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2010-03-30</drugstartdate>
				<drugstartperiod>725</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>ESCITALOPRAM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>TOPAMAX</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>50</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>50 mg, UNK</drugdosagetext>
				<drugdosageform normalized="coated tablet">Coated tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2009-08-25</drugstartdate>
				<drugstartperiod>942</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>TOPIRAMATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LYRICA</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>75</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>75 mg, UNK</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-06-25</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>PREGABALIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012IT079620, is a combined <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from a healthcare <Semaphore x="2425040" class="Occupation" value="Professional Occupation" score="1.00" ID="C75558">professional </Semaphore>(HCP) on 11 Sep 2012 and forwarded by health authority (HA) (HA's number: 175292) on 13 Sep 2012 and follow up report received from a healthcare <Semaphore x="2425040" class="Occupation" value="Professional Occupation" score="1.00" ID="C75558">professional </Semaphore>on 11 Sep 2012 and forwarded by health authority (HA) (HA's number: 175288) on 14 Sep 2012 and follow up report received from a healthcare <Semaphore x="2425040" class="Occupation" value="Professional Occupation" score="1.00" ID="C75558">professional </Semaphore>on 21 Nov 2012 and follow up report received from a healthcare <Semaphore x="2425040" class="Occupation" value="Professional Occupation" score="1.00" ID="C75558">professional </Semaphore>and forwarded by health authority (HA) (HA's number: 175288) on 14 Dec 2012 and follow up received from a quality assurance (QA) department on 21 Jan 2013: This is also a quality complaint (AQWA: 637893). This report refers to a 32-year old female patient. The patient's medical history was not reported. The patient's concomitant medications included Cipralex (<Semaphore x="541059" class="Medicine" value="Escitalopram" score="0.49" ID="252960">escitalopram</Semaphore>), <Semaphore x="1282885" class="Medicine" value="Topamax" score="0.49" ID="249000">Topamax </Semaphore>(<Semaphore x="1283254" class="Medicine" value="topiramate" score="0.49" ID="266066">topiramate</Semaphore>) and <Semaphore x="804590" class="Medicine" value="Lyrica" score="0.74" ID="275868">Lyrica </Semaphore>(<Semaphore x="1082033" class="Medicine" value="pregabalin" score="0.49" ID="239993">pregabalin</Semaphore>). This patient had been treated with <Semaphore x="619890" class="Medicine - Gilenya - Frequency" value="(" score="0.49" ID=""><Semaphore x="619876" class="Medicine - Gilenya - Dose" value="0.5 mg" score="0.49" ID=""><Semaphore x="619905" class="Medicine" value="Gilenya" score="0.99" ID="186396">Gilenya </Semaphore>(<Semaphore x="576754" class="Medicine - fingolimod - Dose" value="0.5 mg" score="0.49" ID=""><Semaphore x="576789" class="Medicine" value="fingolimod" score="0.49" ID="186392">fingolimod</Semaphore>) <Semaphore x="2477139567837185" class="Medicine - fingolimod - Dose" value="0.5 mg" score="0.49" ID="">0.5 mg </Semaphore></Semaphore></Semaphore>
     <Semaphore x="2477212582281217" class="Medicine - fingolimod - Frequency" value="(" score="0.49" ID="">(</Semaphore></Semaphore>batch no: S0023) for <Semaphore x="2245768" class="Disease or Finding" value="Multiple Sclerosis" score="1.00" ID="C3243">multiple sclerosis </Semaphore>from 23 Jan 2012. The patient experienced <Semaphore x="2123258" class="Disease or Finding" value="Loss of Consciousness" score="1.00" ID="C50635">loss of consciousness </Semaphore>on 23 Mar 2012 and 17 Aug 2012. After the episode of 17 Aug 2012 (episode IV), the patient didn’t <Semaphore x="1010955" class="Medicine" value="Perform" score="0.74" ID="188526">perform </Semaphore>tests, but the episode resolved spontaneously without administration of medications and the patient continued to take <Semaphore x="619905" class="Medicine" value="Gilenya" score="0.99" ID="186396">Gilenya</Semaphore>. On 20 Nov 2012, the patient suspended <Semaphore x="619905" class="Medicine" value="Gilenya" score="0.99" ID="186396">Gilenya </Semaphore>due to clinical lack of efficacy. The HCP assessed the relationship between the event <Semaphore x="2123258" class="Disease or Finding" value="Loss of Consciousness" score="1.00" ID="C50635">loss of consciousness </Semaphore>and <Semaphore x="619905" class="Medicine" value="Gilenya" score="0.99" ID="186396">Gilenya </Semaphore>as possible and causality for the event clinical lack of efficacy was not reported. Batch number was sent to local QA for <Semaphore x="3049513" class="MedDRA LLT" value="Investigation" score="1.00" ID="10062026">investigations</Semaphore>. No more information was available.Follow up report received from a healthcare <Semaphore x="2425040" class="Occupation" value="Professional Occupation" score="1.00" ID="C75558">professional </Semaphore>on 11 Sep 2012 and forwarded by health authority (HA) (HA's number: 175288) on 14 Sep 2012: Information related to the <Semaphore x="1805680" class="Procedure" value="Concomitant Therapy" score="1.00" ID="C53630">concomitant medication (<Semaphore x="804590" class="Medicine" value="Lyrica" score="0.74" ID="275868">Lyrica</Semaphore>), therapy </Semaphore>dates of the existing concomitant medications and event occurrence was updated.Follow up report received from a healthcare <Semaphore x="2425040" class="Occupation" value="Professional Occupation" score="1.00" ID="C75558">professional </Semaphore>on 21 Nov 2012: Information related to the patient (patient didn’t <Semaphore x="1010955" class="Medicine" value="Perform" score="0.74" ID="188526">perform </Semaphore>tests, the episode resolved spontaneously without administration of medications and the patient continued to take <Semaphore x="619905" class="Medicine" value="Gilenya" score="0.99" ID="186396">Gilenya</Semaphore>), <Semaphore x="1433842" class="Disease or Finding" value="Addiction" score="1.00" ID="C3479">addition </Semaphore>of new event (clinical lack of efficacy) and action taken with <Semaphore x="619905" class="Medicine" value="Gilenya" score="0.99" ID="186396">Gilenya </Semaphore>(discontinued on 20 Nov 2012) were up dated.Follow up report received from a healthcare <Semaphore x="2425040" class="Occupation" value="Professional Occupation" score="1.00" ID="C75558">professional </Semaphore>and forwarded by health authority (HA) (HA's number: 175288) on 14 Dec 2012: Batch number of <Semaphore x="619905" class="Medicine" value="Gilenya" score="0.99" ID="186396">Gilenya </Semaphore>(S0023) updated. Batch number was sent to local QA for <Semaphore x="3049513" class="MedDRA LLT" value="Investigation" score="1.00" ID="10062026">investigations</Semaphore>.Follow up received from a quality assurance department on 21 Jan 2013: This is also a quality complaint (AQWA: 637893).</narrativeincludeclinical>
				<sendercomment>Medic Comment: The available reported data does not allow for a proper causality assessment. The case has been conservatively assessed as suspected and will be reassessed after the availability of follow up</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>